Gilead, HIV and lenacapavir

Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already under review by the FDA.
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year | After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate,
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is departing after 14 years.
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
(Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a
Barchart on MSN10h
Gilead Sciences - Leader in HIV Medicines
Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
The Financial Express10h
Gilead Sciences: A rare Nasdaq gem with consistent returns across time horizons
To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.
Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
News-Medical.Net on MSN2d
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Fierce Pharma10d
Gilead sets aside $200M for potential settlement over HIV drug speaker program
Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...
Buy Gilead Sciences (GILD) Stock at 52-Week Highs?
Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back ...
Gilead Sciences's Options: A Look at What the Big Money is Thinking
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
Zacks.com on MSN1d
Gilead (GILD) Up 10.3% Since Last Earnings Report: Can It Continue?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.